Bio-Techne (TECH) Other Accumulated Expenses (2020 - 2026)
Bio-Techne (TECH) posted quarterly Other Accumulated Expenses of $2.1 million for Q1 2026, up 15.39% year-over-year from $1.8 million in Q1 2025, and up 32.57% quarter-over-quarter from $1.6 million in Q4 2025.
Analysis
Bio-Techne (TECH) Other Accumulated Expenses (2020 - 2026) Analysis & Trends
Bio-Techne's Other Accumulated Expenses history runs 7 years deep, the most recent figure standing at $2.1 million for Q1 2026.
- In Q1 2026, Other Accumulated Expenses rose 15.39% year-over-year to $2.1 million; the TTM figure through Mar 2026 stood at $2.1 million (up 15.39% YoY), while the FY2025 annual figure was $1.6 million, down 23.52% from the prior year.
- Other Accumulated Expenses for Q1 2026 stood at $2.1 million, up from $1.6 million in the prior quarter.
- The five-year high for Other Accumulated Expenses was $4.5 million in Q3 2025, with the low at $865000.0 in Q1 2023.
- The 5-year median for Other Accumulated Expenses is $2.1 million (2026), against an average of $2.5 million.
- The sharpest annual moves came in 2022 and 2024: Other Accumulated Expenses sank 75.87% in 2022, then soared 240.92% in 2024.
- Bio-Techne's Other Accumulated Expenses stood at $1.3 million in 2022, then surged by 220.32% to $4.2 million in 2023, then sank by 37.7% to $2.6 million in 2024, then tumbled by 40.05% to $1.6 million in 2025, then jumped by 32.57% to $2.1 million in 2026.
- Business Quant data shows TECH's Other Accumulated Expenses at $2.1 million in Q1 2026, $1.6 million in Q4 2025, and $4.5 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Bio-Techne | 11.29 Bn | 11.03 Bn | 211.39 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 4.03 Mn |
| Mar 31, 2026 | 2.09 Mn |
| Dec 31, 2025 | 1.58 Mn |
| Sep 30, 2025 | 4.55 Mn |
| Jun 30, 2025 | 1.65 Mn |
| Mar 31, 2025 | 1.81 Mn |
| Dec 31, 2024 | 2.63 Mn |
| Sep 30, 2024 | 4.27 Mn |
| Jun 30, 2024 | 2.15 Mn |
| Mar 31, 2024 | 2.95 Mn |
| Dec 31, 2023 | 4.23 Mn |
| Sep 30, 2023 | 4.44 Mn |
| Jun 30, 2023 | 1.41 Mn |
| Mar 31, 2023 | 865,000.00 |
| Dec 31, 2022 | 1.32 Mn |
| Sep 30, 2022 | 1.96 Mn |
| Jun 30, 2022 | 1.24 Mn |
| Mar 31, 2022 | 3.08 Mn |
| Dec 31, 2021 | 5.47 Mn |
| Sep 30, 2021 | 3.61 Mn |